

# Contents

<b>1</b>	<b>von Recklinghausen Disease: 130 Years . . . . .</b>	<b>1</b>
	Vincent M. Riccardi	
<b>2</b>	<b>Clinical Diagnosis and Atypical Forms of NF1 . . . . .</b>	<b>17</b>
	Sirkku Peltonen and Minna Pöyhönen	
<b>3</b>	<b>Management and Treatment of “Complex Neurofibromatosis 1” . . .</b>	<b>31</b>
	Rosalie E. Ferner and Susan M. Huson	
<b>4</b>	<b>Mortality in Neurofibromatosis 1 . . . . .</b>	<b>47</b>
	Gareth R. Evans	
<b>5</b>	<b>The Cognitive Profile of NF1 Children: Therapeutic Implications . . . . .</b>	<b>55</b>
	Natalie A. Pride and Kathryn N. North	
<b>6</b>	<b>Clinical Expression of NF1 in Monozygotic Twins . . . . .</b>	<b>71</b>
	Elizabeth K. Schorry and Emily Sites	
<b>7</b>	<b>Value of Whole Body MRI in Patients with NF1 . . . . .</b>	<b>83</b>
	Victor-Felix Mautner	
<b>8</b>	<b>Quality of Life in NF1 . . . . .</b>	<b>93</b>
	Patricia Birch and J.M. Friedman	
<b>9</b>	<b><i>NF1</i> Gene: Promoter, 5' UTR, and 3' UTR . . . . .</b>	<b>105</b>
	Hua Li and Margaret R. Wallace	
<b>10</b>	<b>The Germline Mutational Spectrum in Neurofibromatosis Type 1 and Genotype–Phenotype Correlations . . . . .</b>	<b>115</b>
	David N. Cooper and Meena Upadhyaya	
<b>11</b>	<b>Splicing Mechanisms and Mutations in the <i>NF1</i> Gene . . . . .</b>	<b>135</b>
	Marco Baralle and Diana Baralle	

<b>12</b>	<b><i>NF1</i> Germline and Somatic Mosaicism . . . . .</b>	<b>151</b>
	Ludwine Messiaen and Jing Xie	
<b>13</b>	<b>Deep Intronic <i>NF1</i> Mutations and Possible Therapeutic Interventions . . . . .</b>	<b>173</b>
	Conxi Lázaro, Juana Fernández-Rodríguez, and Eduard Serra	
<b>14</b>	<b><i>NF1</i> Microdeletions and Their Underlying Mutational Mechanisms . . . . .</b>	<b>187</b>
	Hildegard Kehrer-Sawatzki and David N. Cooper	
<b>15</b>	<b>The Somatic Mutational Spectrum of the <i>NF1</i> Gene . . . . .</b>	<b>211</b>
	Meena Upadhyaya, Nadia Chuzhanova, and David N. Cooper	
<b>16</b>	<b>Relationship Between <i>NF1</i> and Constitutive Mismatch Repair Deficiency . . . . .</b>	<b>235</b>
	Katharina Wimmer	
<b>17</b>	<b>Insights into <i>NF1</i> from Evolution . . . . .</b>	<b>253</b>
	Britta Bartelt-Kirbach and Dieter Kaufmann	
<b>18</b>	<b>Modifier Genes in <i>NF1</i> . . . . .</b>	<b>269</b>
	Eric Pasmant, Dominique Vidaud, and Pierre Wolkenstein	
<b>19</b>	<b>Dissection of Complex Genetic and Epigenetic Interactions Underlying <i>NF1</i> Cancer Susceptibility Using Mouse Models . . . . .</b>	<b>287</b>
	Georgette N. Jones and Karlyne M. Reilly	
<b>20</b>	<b>Neurofibromin: Protein Domains and Functional Characteristics . . . . .</b>	<b>305</b>
	Klaus Scheffzek and Stefan Welti	
<b>21</b>	<b>Molecular Basis of Bone Abnormalities in <i>NF1</i> . . . . .</b>	<b>327</b>
	David A. Stevenson and Florent Elefteriou	
<b>22</b>	<b><i>NF1</i>-Associated Optic Glioma . . . . .</b>	<b>341</b>
	Anne C. Solga and David H. Gutmann	
<b>23</b>	<b>Molecular Basis of Cardiovascular Abnormalities in <i>NF1</i> . . . . .</b>	<b>353</b>
	Brian K. Stansfield, David A. Ingram, Simon J. Conway, and Jan M. Friedman	
<b>24</b>	<b>Molecular Basis of Glomus Tumours . . . . .</b>	<b>367</b>
	Hilde Brems, Eric Legius, and Douglas R. Stewart	
<b>25</b>	<b>Pheochromocytoma and <i>NF1</i> . . . . .</b>	<b>381</b>
	Birke Bausch and Hartmut P.H. Neumann	
<b>26</b>	<b>Molecular and Cellular Basis of Human Cutaneous Neurofibromas and Their Development . . . . .</b>	<b>393</b>
	Juha Peltonen, Eeva-Mari Jouhilahti, and Sirkku Peltonen	

**27 Somatic Copy Number Alterations: Gene and Protein Expression Correlates in NF1-Associated Malignant Peripheral Nerve Sheath Tumors . . . . .** 405  
 Meena Upadhyaya and David N. Cooper

**28 Pathologic and Molecular Diagnostic Features of Peripheral Nerve Sheath Tumors in NF1 . . . . .** 429  
 Anat Stemmer-Rachamimov and G. Petur Nielsen

**29 Malignant Peripheral Nerve Sheath Tumors: Prognostic and Diagnostic Markers and Therapeutic Targets . . . . .** 445  
 Holly Meany, Brigitte C. Widemann, and Nancy Ratner

**30 NF1 Mutations in Hematologic Cancers . . . . .** 469  
 Tiffany Chang and Kevin Shannon

**31 Legius Syndrome: Diagnosis and Pathology . . . . .** 487  
 Hilde Brems, Ludwine Messiaen, and Eric Legius

**32 The RASopathies: Syndromes of Ras/MAPK Pathway Dysregulation . . . . .** 497  
 William E. Tidyman and Katherine A. Rauen

**33 Advances in NF1 Animal Models and Lessons Learned . . . . .** 513  
 Ophélie Maertens and Karen Cichowski

**34 Drosophila: An Invertebrate Model of NF1 . . . . .** 523  
 James A. Walker, Jean Y. Gouzi, and André Bernards

**35 Zebrafish Model for NF1 . . . . .** 535  
 Arun Padmanabhan and Jonathan A. Epstein

**36 Cell of Origin and the Contribution of Microenvironment in NF1 Tumorigenesis and Therapeutic Implications . . . . .** 549  
 Johanna Buchstaller, D. Wade Clapp, Luis F. Parada, and Yuan Zhu

**37 Molecular and Cellular Approaches to Cognitive Impairments Associated with NF1 and Other Rasopathies . . . . .** 569  
 Yong-Seok Lee and Alcino J. Silva

**38 Ras Signaling Pathway in Biology and Therapy of Malignant Peripheral Nerve Sheath Tumors . . . . .** 589  
 Faris Farassati

**39 MicroRNA and NF1 Tumorigenesis . . . . .** 611  
 Adrienne M. Flanagan and Nadège Presneau

**40 Translational/Clinical Studies in Children and Adults with Neurofibromatosis Type 1 . . . . .** 625  
 Bruce Korf, Brigitte Widemann, Maria T. Acosta, and Roger J. Packer

**41 The Role of NF1 Lay Foundations: Future Vision . . . . . 659**  
Kim Hunter-Schaedle

**42 Social Stigma in Neurofibromatosis 1 . . . . . 673**  
Joan Ablon

**43 Personalized Medicine in NF1 . . . . . 683**  
David Viskochil

**44 Neurofibromatosis Type 1: Future Directions  
(Where Do We Go from Here?) . . . . . 691**  
Luis F. Parada

**Index . . . . . 699**



<http://www.springer.com/978-3-642-32863-3>

Neurofibromatosis Type 1

Molecular and Cellular Biology

Upadhyaya, M.; Cooper, D. (Eds.)

2012, XVI, 717 p. 75 illus., 60 illus. in color., Hardcover

ISBN: 978-3-642-32863-3